[Skip to Content]
[Skip to Content Landing]
Editorial
June 2018

Precision Medicine and Testing for Tumor Biomarkers—Are All Tests Born Equal?

Author Affiliations
  • 1Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor
JAMA Oncol. 2018;4(6):773-774. doi:10.1001/jamaoncol.2017.4018

We have entered the era of precision oncology medicine, led by technical advances in nucleic acid and protein high throughput analyses and generation of targeted therapeutic agents. Obviously, precision medicine is driven by pathologic evaluation of tumor biomarkers. A deep understanding of tumor biomarker tests is essential, since there can be 1 or more assays for each tumor biomarker, and these may or may not be accurate or provide the same answer. Thus, clinicians must be cognizant not just of the tumor biomarker, but the test used to measure it.

×